CareDx (CDNA) Set to Announce Quarterly Earnings on Thursday

CareDx (NASDAQ:CDNA) will release its earnings data after the market closes on Thursday, May 9th. Analysts expect CareDx to post earnings of ($0.19) per share for the quarter. CareDx has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The company had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The business’s revenue for the quarter was down 20.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.34) EPS. On average, analysts expect CareDx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CareDx Stock Up 2.9 %

Shares of CareDx stock opened at $10.48 on Wednesday. The business has a 50-day moving average price of $9.72 and a 200 day moving average price of $9.43. CareDx has a fifty-two week low of $4.80 and a fifty-two week high of $12.93. The firm has a market cap of $542.65 million, a P/E ratio of -2.96 and a beta of 1.51.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $12.00 to $15.00 in a report on Wednesday, May 1st. Stephens reaffirmed an “overweight” rating and issued a $15.00 price target on shares of CareDx in a report on Wednesday, April 17th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $14.00.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.